|
Seite ohne Frame |
Zur Diskussion über
Nevirapine
Zur Einführung
Briefe von Christian
Fiala und von David Rasnick
open book (pdf, 690 kb):
The trouble with
nevirapine - Anthony Brink
| Aus einem perdönlichen Brief von Christian Fiala, Mitglied von Mbeki's AIDS Advisory Panel und Autor des Buches:
"Lieben wir gefährlich? - Ein Arzt auf der Suche nach den Fakten und Hintergründen von Aids".
Deuticke Verlag Wien. 1997. Vgl: http://www.rethinkingaids.de/allg/buecher.htm#Fiala |
| From: Christian Fiala Date: Sun, 31 Mar 2002 13:08:47 +0200 Subject: Re: Nevirapine [...] ich bin schon einen Monat in Afrika [...]
Zunächst war ich einen Monat in Malawi und jetzt bin ich für 6 Monate in
Uganda. |
| Zu den Wirkungen von Nevirapine siehe auch den Leserbrief von David Rasnick "to the Independent Online of South Africa" (April 2002): |
| Dear Editor, The headline reads: "Nevirapine Does Work, US Researchers Tell SA". Nevirapine does indeed work. Here's what it does according to it's manufacturer: Boehringer Ingelheim Pharmaceuticals, Inc. 2001, Viramune ® (nevirapine) WARNING Severe, life-threatening, and in some cases fatal hepatotoxicity, including fulminant and cholestatic hepatitis, hepatic necrosis and hepatic failure, has been reported in patients treated with VIRAMUNE €€€€. In some cases, patients presented with non-specific prodromal signs or symptoms of hepatitis and progressed to hepatic failure. Some events occurred after short-term exposure to VIRAMUNE. Patients with signs or symptoms of hepatitis must seek medical evaluation immediately and should be advised to discontinue VIRAMUNE. (See WARNINGS) Severe, life-threatening skin reactions, including fatal cases, have occurred in patients treated with VIRAMUNE. These have included cases of Stevens-Johnson syndrome, toxic epidermal necrolysis, and hypersensitivity reactions characterized by rash, constitutional findings, and organ dysfunction. Patients developing signs or symptoms of severe skin reactions or hypersensitivity reactions must discontinue VIRAMUNE as soon as possible. (See WARNINGS) The first 12 weeks of therapy with VIRAMUNE are a critical period during which it is essential that patients be monitored intensively to detect potentially life-threatening hepatotoxicity or skin reactions. VIRAMUNE should not be restarted following severe hepatic, skin or hypersensitivity reactions. In addition, the 14-day lead-in period with VIRAMUNE 200 mg daily dosing must be strictly followed. (See WARNINGS) David Rasnick, PhD Member of Mbeki's AIDS Advisory Panel |